UNITED STATES JUDICIAL PANEL FILED

on MULTIDISTRICT LITIGATION oe Nr 08 2021

IN RE: ZANTAC (RANITIDINE) PRODUCTS

LIABILITY LITIGATION MDL No. 2924

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO —59)

On February 6, 2020, the Panel transferred 12 civil action(s) to the United States District Court for the Southern District of Florida for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. See 437 F.Supp.3d 1368 (J.P.M.L. 2020). Since that time, 310 additional action(s) have been transferred to the Southern District of Florida. With the consent of that court, all such actions have been assigned to the Honorable Robin L. Rosenberg. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Southern District of Florida and assigned to Judge Rosenberg. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the Southern District of Florida for the reasons stated in the order of February 6, 2020, and, with the consent of that court, assigned to the Honorable Robin L. Rosenberg. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Southern District of Florida. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.

———_——___— FOR THE PANEL: pending ats time, the ° LZ stay is lifted. □□ Sh ea

CLERK’S OFFICE

Mon John W. Nichols Clerk of the Panel DISTR on be a true and 56 GSO toga Noble Clr (ee, ay ts bala 2 Heal le J 3 By___ Maria Cruz a 2, ja@puty Clerl owe_Apr 7, 2027

IN RE: ZANTAC (RANITIDINE) PRODUCTS

LIABILITY LITIGATION MDL No. 2924

SCHEDULE CTO−59 − TAG−ALONG ACTIONS

DIST DIV. C.A.NO. CASE CAPTION

CALIFORNIA CENTRAL

Gene Balsom v. Boehringer Ingelheim Pharmaceuticals,

CAC 8 21−00472

Inc. et al

CALIFORNIA EASTERN

Daly v. Boehringer Ingelheim Pharmaceuticals, Inc. et

CAE 2 21−00530

al

PUERTO RICO

PR 3 21−01122 Ferrer v. GlaxoSmithKline LLC et al PR 3 21−01125 Santiago et al v. GlaxoSmithKline LLC et al